References
1. Rawla P. Epidemiology of Prostate Cancer. World JJournal Oncol . 2019;10(2):63-89. doi:10.14740/wjon1191
2. Castillejos-molina RA, Gabilondo-navarro FB. Prostate cancer.Salud Publica Mex . 2016;58(2):279-284.
3. Torres-Sánchez LE, Espinoza-Giacinto R, Rojas-Martínez R, et al. Prostate cancer mortality according to marginalization status in Mexican states from 1980 to 2013. Salud Publica Mex . 2016;58(2):179-186. doi:10.21149/spm.v58i2.7787
4. Reynoso-Noverón N, Torres-Domínguez JA. Epidemiología del cáncer en México : carga global y proyecciones 2000-2020 Epidemiology of cancer in México : global burden and projections 2000-2020. Rev Latinoam Med Conduct . 2017;8(1):9-15.
5. Gomez-Guerra LS, Martinez-Fierro ML, Alcantara-Aragon V, et al. Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases. BMC Cancer . 2009;9(91):1-6. doi:10.1186/1471-2407-9-91
6. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst . 2012;104(2):125-132. doi:10.1093/jnci/djr500
7. Schroder FH, Hugosson J, Roobol MJ, et al. The European Randomized Study of Screening for Prostate Cancer – Prostate Cancer Mortality at 13 Years of Follow-up. Lancet . 2014;384(9959):2027-2035. doi:10.1016/S0140-6736(14)60525-0.The
8. Tsodikov, Alex. Gulati, Roman. Heijnsdijk, Eveline AM. Pinsky, Paul F. Moss SM. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med . 2015;167(7):449-455. doi:10.1038/ncomms5930.Genetic
9. Carter HB, Albertsen PC, Barry MJ, et al. Early Detection of Prostate Cancer: AUA Guideline. J Urol . 2013;190(2):419-426. doi:10.1016/j.juro.2013.04.119
10. Drummond FJ, Carsin A-E, Sharp L, Comber H. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. BMC Fam Pract . 2009;10(1):3. doi:10.1186/1471-2296-10-3
11. Tasian GE, Cooperberg MR, Cowan JE, et al. Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol Semin Orig Investig . 2012;30(2):155-160. doi:10.1016/j.urolonc.2009.12.019
12. Brett J, Watson E, Hewitson P, et al. PSA testing for prostate cancer: An online survey of the views and reported practice of General Practitioners in the UK. BMC Fam Pract . 2005;6:1-6. doi:10.1186/1471-2296-6-24
13. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol . 2014;66(6):1054-1064. doi:10.1016/j.eururo.2014.08.059
14. Zhang L, Wang Y, Qin Z, et al. Correlation between prostatitis, benign prostatic hyperplasia and prostate cancer: A systematic review and meta-analysis. J Cancer . 2020;11(1):177-189. doi:10.7150/jca.37235
15. Catalona WJ, Richie JP, Ahman FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol . 2017;197(25):S200-S207.
16. Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol . 2012;3(2):120-129. doi:10.1007/s13193-012-0142-6
17. Tun Firzara AM, Ng CJ. Knowledge and practice of prostate cancer screening among general practitioners in Malaysia: a cross-sectional study. BMJ Open . 2016;6(9):1-7. doi:10.1136/bmjopen-2016-011467
18. Lajous M, Cooperberg MR, Rider J, et al. Prostate cancer screening in low- and middle- income countries: the Mexican case. Salud Publica Mex . 2019;61(4):542. doi:10.21149/10373
Table 1 . Primary Care Physicians’ characteristics and practice trends related to prostate cancer early detection.